While Eli Lilly has withdrawn its request for European Union (EU) approval of its COVID-19 antibody-based treatment as the EU pivots its focus on other suppliers, the US has agreed to buy 614,000 additional doses of Lilly’s antibody combo for $1.29 billion. The European Medicines Agency (EMA) announced that it halted its review of the cocktail after the U.S.-based drugmaker initially revoked the process. The cocktail, consisting of two monoclonal antibodies (MABs), known as etesevimab and bamlanivimab, has already been approved for emergency use in the US to prevent a worsening of symptoms in patients with COVID-19.
Read more here.
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.